ANTURANE
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTURANE is an oral small-molecule tablet approved in 1959 by Novartis, representing a legacy NDA product with a long clinical history. The specific indication and mechanism of action are not publicly disclosed in this dataset. Patient exposure and clinical positioning cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracting brand team and shift toward generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANTURANE currently shows zero linked job openings, reflecting a mature product with limited hiring activity. Career opportunities are primarily in regulatory compliance, generic transition planning, and customer retention during the LOE period.
Regulatory Affairs SpecialistProduct Manager
Worked on ANTURANE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.